Improving Outcomes in Diabetes: Focus on SGLT2 Inhibitors. A Medical Experts Discussion

Published: 01 April 2021

  • Views:

    Views Icon 4758
  • Likes:

    Heart Icon 7

Overview

Full programme

Part 3 of 5

Derek Connolly

Derek Connolly

Overview

This programme has been created with a view to educate primary care healthcare professionals in the UK to understand when, and for whom, they should prescribe SGLT2 inhibitors and to understand the latest advancements in this drug class.

 

Boehringer Ingelheim Ltd has supported this event as a Medical Education Grant and has had no other involvement in the organisation or the delivery of this programme.

Key Learning Objectives

  • Describe how and when to prescribe SGLT2 inhibitors
  • Identify patients who are suitable for SGLT2 inhibitors
  • Provide appropriate patient education and advice when initiating SGLT2 inhibitors
  • Recall the patient populations in whom SGLT2 inhibitors have proven efficacy and safety

Faculty

  • Dr Jas Gill - GP with Special Interest in Cardiology
  • Dr Andrew Frankel - Consultant Nephrologist
  • Dr Derek Connolly - Consultant Interventional Cardiologist
  • Su Down - Nurse Consultant in Diabetes

More from this programme

Part 1

Welcome and Introductions

Part 2

SGLT2 inhibitors: Initiation in Diabetic Kidney Disease

Part 3

SGLT2 Inhibitors in Heart Failure

Part 4

Practical aspects of initiating in Diabetes

1 session
Su Down Watch now

Part 5

Practical Prescribing

1 session
Jas Gill Watch now

Faculty Biographies

Derek Connolly

Derek Connolly

Consultant Interventional Cardiologist

Dr Derek Connolly is a Consultant Interventional Cardiologist and the Director of Research and Development at Birmingham City Hospital. He is an Honorary Senior Clinical Lecturer at the Institute of Cardiovascular Sciences, University of Birmingham, UK.

He trained in Edinburgh, Cambridge, London and San Diego where he was a Carnegie Scholar. He has a first class degree in Pharmacology from the University of Edinburgh where he was the Brunton medallist and Keasbey Bursary holder. His BHF funded PhD in molecular cardiology is from the University of Cambridge. He is the Chief or Primary Investigator of multiple large trials in Cardiovascular medicine. He developed one of the UKs first primary angioplasty programmes, and one of the UKs largest cardiac CT programmes.

He was on the design and naming team of the forthcoming super hospital, the Midland Metropolitan University Hospital which will open 2022.

Dr Derek Connolly is on the…

View full profile